亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Phase Ⅱ,Open-Label, Multicenter, Single-Arm Study Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea(HU)

真性红细胞增多症 医学 多中心研究 打开标签 不利影响 内科学 临床试验 临床研究阶段 外科 随机对照试验
作者
Jie Jin,Lei Zhang,Zonghong Shao,Jie Bai,Suning Chen,Minghui Duan,Sujiang Zhang,Hu Zhou,Na Xu,Xin Du,Xuelan Zuo,Li Wang,Pei Li,Xuhan Zhang,Daoxiang Wu,Yaning Li,Jingjing Zhang,Wei Wang,Warren Shen,Oleh Zagrijtschuk,Raymond Urbanski,Toshiaki Sato,Albert Qin,Zhijian Xiao
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 6858-6859
标识
DOI:10.1182/blood-2022-165789
摘要

Background: Polycythemia vera (PV) is a common type of BCR-ABL-negative myeloproliferative neoplasms. It often harbors a Janus kinase 2 (JAK2) gene mutation and is associated with elevated blood cell counts, symptoms that can be debilitating over time and risks of thrombosis and hemorrhage, and disease progression to myelofibrosis and acute myeloid leukemia. Ropeginterferon alfa-2b, a novel, site-selective, mono-pegylated proline-interferon alfa-2b, has improved pharmacokinetic properties, allowing dosing every 2 to 4 weeks, with improved tolerability and convenience. The safety and efficacy of ropeginterferon alfa-2b for the treatment of PV has been demonstrated in clinical studies conducted in Europe (PEGINVERA, PROUD-PV, CONTINUATION-PV) and Japan. The approved dosing scheme of ropeginterferon alfa-2b is 100 μg (or 50 μg in patients under another cytoreductive therapy) as a starting dose, with dose increment of 50 μg to the maximum recommended dose of 500 μg. Faster dose escalation may help patients achieve control of hematologic parameters quicker. Aims: The aim of this phase Ⅱ, single-arm study (A20-202) was to assess the safety and efficacy of ropeginterferon alfa-2b in Chinese PV patients utilizing an accelerated dose titration schedule. Methods: Chinese patients 18 years or older with a PV diagnosis according to World Health Organization 2016 criteria and were resistant or intolerant to hydroxyurea (HU) were enrolled. Ropeginterferon alfa-2b was administered subcutaneously every 2 weeks for 52 Weeks at a starting dose of 250 μg, followed by 350 µg at Week 2, and a target dose of 500 μg at Week 4. Patients received the target dose, if tolerated, for the remainder of the 52-week treatment. The primary endpoint was the proportion of patients who reach a complete hematologic response (CHR) at Week 24 (CHR: hematocrit <45% without phlebotomy or erythrocyte apheresis in the preceding 12 weeks, platelet≤400×109/L, leukocyte <10×109/L). Secondary endpoints included changes in hematologic parameters and JAK2V617F allele burden, time to first complete hematologic response, and duration of response. Safety endpoints included the incidence of treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI). Results: As of the data cut-off date of 01 July 2022, a-total of 49 patients, 31 males and 18 females, with a median age of 56 years, were enrolled in this study. Mean baseline values were hematocrit 45.95%, leukocyte count 11.35×109/L, and platelet count 478.5×109/L. All patients had the JAK2V617F mutation (mean allele burden: 58.49%). One patient withdrew consent and discontinued the study. The data of 27 patients were available to evaluate the CHR at Week 24. Fourteen out of the 27 (51.85%) patients achieved a CHR at Week 24 of the treatment. This was comparable to the CHR rate of 43.1% at Week 52 observed in the PROUD-PV study. Hematocrit, leukocyte and platelet levels decreased over time with mean change ± SD from baseline to Week 24: -3.63± 6.14%, -5.77± 12.22×109/L, and -254.0± 177.23×109/L, respectively. JAK2V617F allele burden decreased over time with mean change ± SD from baseline to week 24: -13.95±16.74% (n=26); consistent with an increase in molecular response. The JAK2V617F allele burden in two patients became undetectable after the treatment, as measured by Next-Generation Sequencing with a lower limit of quantitation at 3% by the central laboratory. TEAEs occurred in 47 patients (95.9%). Grade≥3 AEs occurred in 8 of the patients (16.3%) and among them, possibly treatment-related Grade ≥ 3 AEs occurred in five patients (10.2%). Serious adverse events (SAE) occurred in 4 of the patients (8.2%), and possibly treatment-related SAE occurred in two patients (4.1%). The most common TEAEs were alanine aminotransferase increase (38.8%), leukopenia (36.7%) and aspartate aminotransferase increase (36.7%). Preliminary result did not show significant AESIs (e.g., cardiovascular and psychiatric events) in all the patients who received the treatment. Summary/Conclusion: The interim results of our study demonstrate that Ropeginterferon alfa-2b using a 250-350-500 μg dosing scheme was safe, well tolerated, and efficacious in Chinese patients with PV. The data suggest that using an accelerated dosing scheme helps patients achieve a CHR earlier.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
maki完成签到,获得积分10
4秒前
q2026完成签到 ,获得积分20
4秒前
123完成签到,获得积分10
5秒前
缓慢的秋荷完成签到,获得积分10
5秒前
Laluna的应助被suicone采纳,获得10
6秒前
巨型肥猫发布了新的文献求助10
6秒前
10秒前
10秒前
肉袒牵洋完成签到 ,获得积分10
13秒前
欢喜的不尤完成签到,获得积分10
14秒前
神勇的筝发布了新的文献求助30
15秒前
bkagyin的应助被兴奋小蚂蚁采纳,获得10
16秒前
16秒前
17秒前
18秒前
whs关闭了whs的文献求助
20秒前
DOC_XIONG的应助被涵泽采纳,获得10
25秒前
26秒前
yangyang完成签到 ,获得积分10
26秒前
沉静代秋完成签到,获得积分20
26秒前
sss完成签到 ,获得积分10
27秒前
可靠的公爵熊完成签到,获得积分10
30秒前
三四月完成签到 ,获得积分10
31秒前
文静楷瑞完成签到,获得积分10
32秒前
花痴的善若完成签到,获得积分10
33秒前
zzl完成签到 ,获得积分10
33秒前
跳跃的乐曲完成签到,获得积分10
34秒前
vanilla完成签到,获得积分10
34秒前
兴奋小蚂蚁完成签到,获得积分10
35秒前
咕噜咕噜完成签到 ,获得积分10
36秒前
39秒前
乐乐的应助被开心的中心采纳,获得10
41秒前
Anserbe完成签到,获得积分10
41秒前
41秒前
41秒前
43秒前
orixero的应助被科研通管家采纳,获得10
43秒前
英俊的铭的应助被科研通管家采纳,获得10
43秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179656
求助须知:如何正确求助?哪些是违规求助? 9569921
关于积分的说明 21807706
捐赠科研通 7775141
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478778